PRINCIPAL FINANCIAL GROUP INC - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 265 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.

Quarter-by-quarter ownership
PRINCIPAL FINANCIAL GROUP INC ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q3 2023$21,669,548
-18.1%
416,002
-0.4%
0.02%
-11.1%
Q2 2023$26,457,250
+1994.6%
417,834
+1691.3%
0.02%
+1700.0%
Q1 2023$1,263,103
-4.3%
23,326
-6.4%
0.00%0.0%
Q4 2022$1,319,243
-38.2%
24,929
-45.7%
0.00%
-50.0%
Q3 2022$2,135,000
-80.6%
45,876
-76.1%
0.00%
-75.0%
Q2 2022$10,978,000
+171.8%
192,341
+191.4%
0.01%
+166.7%
Q1 2022$4,039,000
+15.9%
66,003
-0.9%
0.00%
+50.0%
Q4 2021$3,485,000
+197.9%
66,580
+112.2%
0.00%
+100.0%
Q3 2021$1,170,000
-4.4%
31,372
+4.6%
0.00%0.0%
Q2 2021$1,224,000
+46.6%
29,980
+21.8%
0.00%0.0%
Q1 2021$835,000
+14.7%
24,616
+7.5%
0.00%0.0%
Q4 2020$728,000
+106.2%
22,892
+66.2%
0.00%
Q3 2020$353,000
-1.7%
13,775
-1.4%
0.00%
Q2 2020$359,000
+30.1%
13,969
+73.4%
0.00%
Q4 2019$276,000
+11.7%
8,054
+75.0%
0.00%
Q4 2015$247,0004,6010.00%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q2 2022
NameSharesValueWeighting ↓
Ally Bridge Group (NY) LLC 175,000$9,115,75010.70%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 317,856$16,547,5835.57%
Deep Track Capital, LP 2,600,000$135,434,0005.23%
SUVRETTA CAPITAL MANAGEMENT, LLC 1,369,849$71,355,4343.86%
SILVERARC CAPITAL MANAGEMENT, LLC 208,730$10,872,7463.30%
DCF Advisers, LLC 107,157$5,581,8083.04%
Bellevue Group AG 3,170,250$165,138,3232.66%
Vahanian & Associates Financial Planning Inc. 15,217$792,6542.55%
Iron Triangle Partners LP 330,549$17,218,2972.52%
TANG CAPITAL MANAGEMENT LLC 300,000$15,627,0002.20%
View complete list of INTRA CELLULAR THERAPIES INC shareholders